Proactiveinvestors recommends
Additional Information
Market: AMEX
Sector: Pharmaceuticals & Biotechnology
EPIC: RNN
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Rexahn Pharmaceuticals
www.rexahn.com

Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Full Rexahn Pharmaceuticals profile here
Is RNN a Buy, Sell or Hold?Get your FREE analysis of RNN
Pdf

Rexahn says study shows neuroprotective effects of clavulanic acid, main ingredient in Seradaxin drug

22nd Sep 2010, 8:34 am

Clinical stage pharma company Rexahn Pharmaceuticals (NYSE Amex: RNN) said Tuesday that a published Drug Development Research article indicates that clavulanic acid, the active ingredient of the company's lead central nervous system drug Seradaxin, protects neurons from brain damage associated with neurodegnerative disease.

In the study, rodents that were exposed to different neurotoxins, were administered with clavulanic acid, which protected neurons in the hippocampus and dopaminergic regions of the brain that are critical in Alzheimer's and Parkinson's disease, respectively.

"The exciting neuronal protective properties of clavulanic acid make it a highly promising treatment for neuronal cell death diseases like Parkinson's and Alzheimer's," said Rexahn CEO Chang Ahn.

Parkinson's disease afflicts five million people worldwide, and with the aging of the baby boom generation, that population is expected to double by 2030.

According to the Alzheimer's Association, by 2050, the number of Americans aged 65 and older with Alzheimer's is projected to reach between 11 million and 16 million, unless medical breakthroughs can prevent or more effectively treat the disease.

Currently, Alzheimer's and Parkinson's therapies only provide symptomatic relief.

"Clavulanic acid has breakthrough potential of shielding the brain cell survival mechanisms, rather than fighting one-by-one the multitude of triggers that can activate the cell death mechanisms common in Alzheimer's and Parkinson's," added Ahn.

Alzheimer's has at least five major triggers, while Parkinson's has three major dysfunctioning mechanisms. Rather than intercepting and fighting each trigger, clavulanic acid has shown to broadly protect brain cell mechanisms.

Rexahn develops and commercializes therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. The company currently has three drug candidates in Phase II clinical trials, including Archexin, Serdaxin, and Zoraxel.

The company rallied more than 3% Tuesday morning, to trade at $1.24 on NYSE Amex Exchange.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.